Mark Mirochnick

Summary

Affiliation: Boston University
Country: USA

Publications

  1. ncbi request reprint Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose
    Mark Mirochnick
    Boston University School of Medicine, Boston Medical Center, 91 Concord Street, 6th Floor, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 33:153-6. 2003
  2. ncbi request reprint Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA
    J Acquir Immune Defic Syndr 39:189-94. 2005
  3. pmc Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy
    Mark Mirochnick
    Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Antimicrob Agents Chemother 53:1170-6. 2009
  4. pmc Reduced indinavir exposure during pregnancy
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand Harvard School of Public Health, Boston, MA, USA Institut de Recherché pour le Développement IRD, UMI 174 PHPT, Marseille, France
    Br J Clin Pharmacol 76:475-83. 2013
  5. pmc Atazanavir pharmacokinetics with and without tenofovir during pregnancy
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA
    J Acquir Immune Defic Syndr 56:412-9. 2011
  6. pmc Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA
    Pediatr Infect Dis J 30:769-72. 2011
  7. ncbi request reprint Concentrations of protease inhibitors in cord blood after in utero exposure
    Mark Mirochnick
    Boston University School of Medicine, and Statistical and Data Analysis Center Harvard School of Public Health, Boston, MA, USA
    Pediatr Infect Dis J 21:835-8. 2002
  8. ncbi request reprint Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial
    Alejandro Dorenbaum
    Department of Pediatrics, University of California, San Francisco, USA
    JAMA 288:189-98. 2002
  9. pmc Lopinavir exposure with an increased dose during pregnancy
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, and Infectious Disease Division, Children s Hospital Boston, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 49:485-91. 2008
  10. pmc A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Clin Infect Dis 54:285-93. 2012

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose
    Mark Mirochnick
    Boston University School of Medicine, Boston Medical Center, 91 Concord Street, 6th Floor, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 33:153-6. 2003
    ..To evaluate cord blood and predose nevirapine concentrations in infants exposed to the two-dose intrapartum neonatal nevirapine regimen...
  2. ncbi request reprint Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA
    J Acquir Immune Defic Syndr 39:189-94. 2005
    ..Further investigations of larger doses, such as 75 mg/kg twice a day, should be undertaken...
  3. pmc Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy
    Mark Mirochnick
    Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Antimicrob Agents Chemother 53:1170-6. 2009
    ..The extent and effect of infant drug exposure via breast milk must be well understood in order to evaluate the benefits and risks of maternal antiretroviral use during lactation...
  4. pmc Reduced indinavir exposure during pregnancy
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand Harvard School of Public Health, Boston, MA, USA Institut de Recherché pour le Développement IRD, UMI 174 PHPT, Marseille, France
    Br J Clin Pharmacol 76:475-83. 2013
    ..To describe the pharmacokinetics and safety of indinavir boosted with ritonavir (IDV/r) during the second and third trimesters of pregnancy and in the post-partum period...
  5. pmc Atazanavir pharmacokinetics with and without tenofovir during pregnancy
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA
    J Acquir Immune Defic Syndr 56:412-9. 2011
    ..Few data are available describing atazanavir exposure during pregnancy, especially when used in combination with tenofovir, whose coadministration with atazanavir results in decreased atazanavir exposure...
  6. pmc Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA
    Pediatr Infect Dis J 30:769-72. 2011
    ..There are no previous data describing nelfinavir and lamivudine pharmacokinetics in neonates treated with weight-band dosing regimens...
  7. ncbi request reprint Concentrations of protease inhibitors in cord blood after in utero exposure
    Mark Mirochnick
    Boston University School of Medicine, and Statistical and Data Analysis Center Harvard School of Public Health, Boston, MA, USA
    Pediatr Infect Dis J 21:835-8. 2002
    ..To determine the concentrations of protease inhibitors in cord blood after prenatal protease inhibitor use by pregnant women...
  8. ncbi request reprint Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial
    Alejandro Dorenbaum
    Department of Pediatrics, University of California, San Francisco, USA
    JAMA 288:189-98. 2002
    ..However, it is unknown whether the addition of the 2-dose nevirapine regimen to standard ART would further reduce perinatal HIV transmission...
  9. pmc Lopinavir exposure with an increased dose during pregnancy
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, and Infectious Disease Division, Children s Hospital Boston, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 49:485-91. 2008
    ..The goal of this study was to determine LPV exposure during the third trimester of pregnancy and 2 weeks postpartum with a higher LPV/RTV dose...
  10. pmc A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Clin Infect Dis 54:285-93. 2012
    ..We hypothesized that increasing the duration or potency of the tail would further reduce this risk to <10%, using a sensitive assay to measure resistance...
  11. pmc Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD HIV AIDS Research Department, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Rio Grande do Sul, Brazil Department of Pediatrics, David Geffen UCLA School of Medicine, Los Angeles, CA Malawi College of Medicine, Blantyre, Malawi Infectious Diseases Department, Hospital Federal dos Servidores do Estado, Rio de Janiero, Brazil Department of Pediatrics, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil Serviço de Infectologia, Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande do Sul, Brazil Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD Gilead Sciences, Foster City, CA Statistical Center for HIV AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD Family Health International, Durham, NC Makerere University Johns Hopkins University Research Collaboration, Kampala, Brazil
    J Acquir Immune Defic Syndr 65:33-41. 2014
    ..Data describing the pharmacokinetics and safety of tenofovir in neonates are lacking...
  12. ncbi request reprint Nevirapine concentrations in newborns receiving an extended prophylactic regimen
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 47:334-7. 2008
    ..The optimal neonatal antiretroviral (ARV) regimen for prevention of HIV mother-to-child transmission (MTCT) is unknown for infants born to mothers who receive no ARVs during pregnancy...
  13. ncbi request reprint Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment
    Roger L Shapiro
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, and Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Infect Dis 192:720-7. 2005
    ..The magnitude of infant antiretroviral (ARV) exposure from breast milk is unknown...
  14. pmc Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women
    Tim R Cressey
    Harvard School of Public Health, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 53:2189-91. 2009
    ..2 (8.0 to 17.5) microg/ml, and 4.6 (1.7 to 12.5) microg/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported...
  15. ncbi request reprint Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    J Acquir Immune Defic Syndr 38:283-8. 2005
    ..To determine nevirapine (NVP) plasma levels during the postpartum period after a single intrapartum NVP dose for the prevention of mother-to-child transmission...
  16. ncbi request reprint Pharmacokinetics of antiretrovirals in pregnant women
    Mark Mirochnick
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Clin Pharmacokinet 43:1071-87. 2004
    ..Further investigations of antiretroviral pharmacology during pregnancy, including protein binding studies, are urgently needed...
  17. doi request reprint Antiretroviral pharmacology: special issues regarding pregnant women and neonates
    Mark Mirochnick
    Division of Neonatology, Department of Pediatrics, Boston University School of Medicine, 771 Albany Street Dowling 4111, Boston, MA 02118, USA
    Clin Perinatol 37:907-27, xi. 2010
    ..This article reviews current knowledge of the pharmacology of these drugs during pregnancy and in the newborn period, highlighting those pharmacologic issues critical to the safe and effective use of antiretrovirals in these populations...
  18. pmc Effect of training traditional birth attendants on neonatal mortality (Lufwanyama Neonatal Survival Project): randomised controlled study
    Christopher J Gill
    Center for Global Health and Development, Boston University, Boston, MA, USA
    BMJ 342:d346. 2011
    ..To determine whether training traditional birth attendants to manage several common perinatal conditions could reduce neonatal mortality in the setting of a resource poor country with limited access to healthcare...
  19. ncbi request reprint Pharmacokinetics and tolerance of zidovudine in preterm infants
    Edmund V Capparelli
    University of California, San Diego, USA
    J Pediatr 142:47-52. 2003
    ..To determine zidovudine pharmacokinetics and tolerance in premature human human immunodeficiency virus-exposed infants...
  20. ncbi request reprint Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial
    J Brooks Jackson
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Lancet 362:859-68. 2003
    ..Safety and efficacy data are now presented for all babies followed up to 18 months of age...
  21. ncbi request reprint Pharmacotherapy of perinatal HIV
    Edmund Capparelli
    University of California, San Diego, Pediatric Pharmacology Research Unit, 4094 Fourth Street 201, San Diego, CA 92103, USA
    Semin Fetal Neonatal Med 10:161-75. 2005
    ..Although difficult to perform, clinical trials to determine the safety, pharmacokinetics and optimal dosing of antiretroviral in pregnant women and their newborns are urgently needed...
  22. ncbi request reprint Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission
    J Brooks Jackson
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    AIDS 20:217-22. 2006
    ..To correlate nevirapine presence and concentration in cord bloods of infants born to HIV-1 infected women with report of timing of dose and HIV-1 transmission at 6 weeks of age...
  23. ncbi request reprint Impact of pregnancy on abacavir pharmacokinetics
    Brookie M Best
    University of California San Diego, California 92103 8214, USA
    AIDS 20:553-60. 2006
    ..To describe abacavir pharmacokinetics during pregnancy and postpartum; physiological changes during pregnancy are known to affect antiretroviral drug disposition...
  24. ncbi request reprint Reduced lopinavir exposure during pregnancy
    Alice M Stek
    Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, CA, USA
    AIDS 20:1931-9. 2006
    ..Pregnancy can alter antiretroviral pharmacokinetics. Our objective was to describe lopinavir/ritonavir (LPV/r) pharmacokinetics during pregnancy...
  25. pmc Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants
    Adriana H Tremoulet
    Division of Pharmacology and Drug Discovery, Pediatric Pharmacology Research Unit, University of California San Diego, MC 8214, San Diego, CA 92103 8214, USA
    Antimicrob Agents Chemother 51:4297-302. 2007
    ....